MALDI TOF mass spectrometry (MS) is widely used to characterise and biotype bacterial samples, but a complementary method for profiling of mammalian cells is still underdeveloped. Current approaches vary dramatically in their sample preparation methods and are not suitable for high-throughput studies. In this work, we present a universal workflow for mammalian cell MALDI TOF MS analysis and apply it to distinguish ground-state naïve and differentiating mouse embryonic stem cells (mESCs), which can be used as a model for drug discovery. We employed a systematic approach testing many parameters to evaluate how efficiently and reproducibly each method extracted unique mass features from four different human cell lines. These data enabled us to develop a unique mammalian cell MALDI TOF workflow involving a freeze-thaw cycle, methanol fixing and a CHCA matrix to generate spectra that robustly phenotype different cell lines and are highly reproducible in peak identification across replicate spectra. We applied our optimised workflow to distinguish naïve and differentiating populations using multivariate analysis and reproducibly identify unique features. We were also able to demonstrate the compatibility of our optimised method for current automated liquid handling technologies. Consequently, our MALDI TOF MS profiling method enables identification of unique features and robust phenotyping of mESC differentiation in under 1 hour from culture to analysis, which is significantly faster and cheaper when compared with conventional methods such as qPCR. This method has the potential to be automated and can in the future be applied to profile other cell types and expanded towards cellular MALDI TOF MS screening assays.

Download full-text PDF

Source
http://dx.doi.org/10.1039/c9an00771gDOI Listing

Publication Analysis

Top Keywords

maldi tof
24
embryonic stem
8
tof mass
8
mass spectrometry
8
sample preparation
8
mammalian cell
8
cell maldi
8
naïve differentiating
8
cell lines
8
unique features
8

Similar Publications

Background: Carbapenem-resistant Klebsiella pneumoniae (CRKP) is a difficult to treat organism owing to limited therapeutic options. So far, little is known about the molecular characteristics of CRKP in Palestine.

Objectives: The aim of this study was to investigate the antimicrobial resistance patterns, multilocus sequence types (ST) and resistance genes among clinical K.

View Article and Find Full Text PDF

Biomarkers.

Alzheimers Dement

December 2024

Neurophysiology & Behaviour Lab, University of Castilla-La Mancha, Ciudad Real, Spain.

Background: A key neuropathological feature in the early stages of Alzheimer's disease (AD) involves hippocampal dysfunction arising from the accumulation of amyloid-β (Aβ). Previously, our laboratory identified a shift in the synaptic plasticity long term potentiation (LTP)/long term depression (LTD) induction threshold, leading to memory deficits in a non-transgenic murine model of early AD generated by intracerebroventricular (icv.) injections Aβ oligomers (oAβ), one of the most predominant pathogenetic factors in initial stages of the disease.

View Article and Find Full Text PDF

Biomarkers.

Alzheimers Dement

December 2024

Faculty of Medicine, Oita University, Oita, Japan.

Background: Abnormal amyloid-β (Aβ) deposition in the brain has been defined as the earliest pathological change of Alzheimer disease (AD). Immunoprecipitation coupled with MALDI-TOF MS (IP-MS) has previously revealed that APP669-711/Aβ1-42 ratio, Aβ1-40/Aβ1-42 ratio, and a combination of these two biomarkers (a composite biomarker) in human plasma correlates highly with SUVR obtained from amyloid PET. In this work, we investigate the usefulness of plasma Aβ biomarkers at baseline in predicting the conversion to AD dementia.

View Article and Find Full Text PDF

Biomarkers.

Alzheimers Dement

December 2024

Department of Psychiatry, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.

Background: Amyloid β (Aβ) deposition in the brain is a pathological hallmark of Alzheimer's disease (AD). While immunoprecipitation-mass spectrometry (IP-MS) stands out as an accurate method for quantifying blood-based Aβ peptides, its major limitations such as prolonged sample preparation, extensive analysis time, large specimen volume, and high costs, present opportunities for improvement. Consequently, we aimed to develop a novel plasma IP-MS Aβ assay that employs simplified and significantly shorter analytical procedures, along with much-reduced sample volumes.

View Article and Find Full Text PDF

Biomarkers.

Alzheimers Dement

December 2024

Adeptrix Corp, Beverly, MA, USA.

Background: The rapidly growing pipeline of target-specific Alzheimer's Disease (AD) therapeutic candidates requires accompanying tests that can identify patients likely to have a beneficial response. The growing importance of multiple pathologies in determining AD progression and treatment response underscores this need. Our work focuses on establishing analytical capability to expand detectable forms of major protein drug targets for AD: Tau, amyloid beta (Ab) and a-Synuclein (aS) proteoforms as potential personalized molecular signatures.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!